{"altmetric_id":510234,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["LaraPizzorno"],"posts_count":1}},"selected_quotes":["2\/3 of patients refuse 2nd annual IV of the bisphosphonate, zoledronate (Reclast, Aclasta, Zometa), ADRs are so bad"],"citation":{"abstract":"The present study evaluates the proportion of patients who had re-infusion of intravenous zoledronate after first administration and identifies the factors that contribute to discontinuation.","abstract_source":"pubmed","altmetric_jid":"4f6fa5113cf058f61000326e","doi":"10.1007\/s00198-011-1881-x","first_seen_on":"2011-12-29T00:49:19+00:00","issns":["1433-2965"],"journal":"Osteoporosis International","last_mentioned_on":1325118911,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22179417?dopt=Abstract"],"pmid":"22179417","pubdate":"2011-12-17T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["metabolism","orthopedics"],"title":"Persistence with intravenous zoledronate in elderly patients with osteoporosis.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/persistence-intravenous-zoledronate-elderly-patients-osteoporosis"},"altmetric_score":{"score":0.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.5},"context_for_score":{"all":{"total_number_of_other_articles":3629240,"mean":4.9358355666342,"rank":2743498,"this_scored_higher_than_pct":20,"this_scored_higher_than":727789,"rank_type":"exact","sample_size":3629240,"percentile":20},"similar_age_3m":{"total_number_of_other_articles":232190,"mean":3.9206882755,"rank":148302,"this_scored_higher_than_pct":28,"this_scored_higher_than":65296,"rank_type":"exact","sample_size":232190,"percentile":28},"this_journal":{"total_number_of_other_articles":885,"mean":3.0671063348416,"rank":489,"this_scored_higher_than_pct":35,"this_scored_higher_than":318,"rank_type":"exact","sample_size":885,"percentile":35},"similar_age_this_journal_3m":{"total_number_of_other_articles":42,"mean":1.2856097560976,"rank":19,"this_scored_higher_than_pct":40,"this_scored_higher_than":17,"rank_type":"exact","sample_size":42,"percentile":40}}},"demographics":{"poster_types":{"practitioner":1},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Librarian":1,"Student  > Ph. D. Student":2,"Student  > Master":1,"Other":2,"Professor":1},"by_discipline":{"Medicine and Dentistry":6,"Social Sciences":1,"Business, Management and Accounting":1}}},"geo":{"twitter":{"US":1},"mendeley":{"KR":1,"CH":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/#!\/LaraPizzorno\/status\/152185862350843904","citation_ids":[510234],"posted_on":"2011-12-29T00:35:11+00:00","author":{"name":"Lara Pizzorno","url":"http:\/\/www.lmreview.com","image":"https:\/\/pbs.twimg.com\/profile_images\/692343717\/Lara_Professional_small_version_normal.JPG","description":"Editor, Longevity Medicine Review -- analyzing the latest research in longevity science @\r\nhttp:\/\/www.lmreview.com; Senior Medical Editor, SaluGenecists, Inc.","id_on_source":"LaraPizzorno","tweeter_id":"113772171","geo":{"lt":47.60621,"ln":-122.33207,"country":"US"},"followers":1717},"tweet_id":"152185862350843904"}]}}